Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Newron Pharmaceut. Stock

Price
Target price
€1.72

€1.72

-4.820%
-0.08
-4.820%
€6.50

€6.50

 
Latest predictions
-
15.05.20
buy
-
14.04.20
buy
€6.50
05.03.20
buy
Your prediction

Newron Pharmaceut. Stock

Newron Pharmaceut. took a tumble today and lost -€0.080 (-4.820%).
Our community is currently high on Newron Pharmaceut. with 3 Buy predictions and 0 Sell predictions.
With a target price of €6.00 there is potential for a 248.837% increase which would mean more than doubling the current price of €1.72 for Newron Pharmaceut..
Register To Post

Other discussions about Newron Pharmaceut. Stock

New thread

News

Newron AGM Result and Clinical and Business Update


Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Newron Updates On STARS Study FDA Interaction


Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia


Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

DGAP-News: Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
DGAP-News: Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome

DGAP-News: Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome

DGAP-News: Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB): https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
DGAP-News: Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)

DGAP-News: Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)

DGAP-News: Newron AGM Result and Clinical and Business Update : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
DGAP-News: Newron AGM Result and Clinical and Business Update

DGAP-News: Newron AGM Result and Clinical and Business Update

DGAP-News: Newron updates on STARS study FDA interaction: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
DGAP-News: Newron updates on STARS study FDA interaction

DGAP-News: Newron updates on STARS study FDA interaction

DGAP-News: Newron announces 2019 financial results and provides outlook for 2020: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
DGAP-News: Newron announces 2019 financial results and provides outlook for 2020

DGAP-News: Newron announces 2019 financial results and provides outlook for 2020

DGAP-News: Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia

DGAP-News: Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia

DGAP-News: Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA

DGAP-News: Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA

DGAP-Adhoc: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

DGAP-Adhoc: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

DGAP-News: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

DGAP-News: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data